The rally in SMMT stock is driven by encouraging updates on its oncology candidate, which has the potential to become the ...

Indaptus Therapeutics (INDP) announced a clinical supply agreement with BeiGene (BGNE). Building on Indaptus’ preclinical observation ...

Recent advancements in protein engineering, especially antibody-drug conjugates, show promise in lung cancer treatment, with ...

Regeneron spent $5 billion repurchasing shares from Sanofi in May 2020 and $900 million repurchasing global rights to Libtayo in July 2022, yet a windfall from sales of its Covid antibody cocktail as ...

BriaCell Therapeutics could access a $1-$5 billion market upon approval despite a sub-$30 million cap. See more on BRIA stock ...

Under Indaptus' clinical supply agreement with BeiGene, the New York biotechnology company plans to advance human clinical evaluation of its cancer treatment -- called Decoy20, which is being studied ...

( MENAFN - GlobeNewsWire - Nasdaq) Planned industry first clinical trial combining BeiGene's checkpoint inhibitor tislelizumab with Indaptus' broadly targeted, short duration systemic immune ...

SOTIO Biotech, a clinical-stage immuno-oncology company owned by PPF Group, today announced it will present three posters at the 2024 Society for Immunotherapy of Cancer Meeting taking place November ...

SOTIO Biotech, a clinical-stage immuno-oncology company owned by PPF Group, today announced it will present three posters at the 2024 Society for Immunotherapy of Cancer Meeting taking place November ...

After raising $42 million in a series C1 round, Lanova Medicines Ltd. is advancing its lead phase III antibody-drug conjugate ...

Seaport Therapeutics Inc. has followed up its recent fundraiser with an oversubscribed $225 million series B financing that will help set it on the path to a phase IIb study of major depressive ...

The large inflow of cash from Comirnaty gross profits in 2021-22 has further secured BioNTech's financial health. Outside of BioNTech’s covid-19 vaccine candidates, we think the earliest approval ...